×
S&P 500   3,785.38 (-0.88%)
DOW   30,775.43 (-0.82%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
S&P 500   3,785.38 (-0.88%)
DOW   30,775.43 (-0.82%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
S&P 500   3,785.38 (-0.88%)
DOW   30,775.43 (-0.82%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
S&P 500   3,785.38 (-0.88%)
DOW   30,775.43 (-0.82%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
NASDAQ:AVRO

AVROBIO Stock Forecast, Price & News

$0.92
-0.09 (-8.91%)
(As of 06/30/2022 05:48 PM ET)
Add
Compare
Today's Range
$0.92
$1.00
50-Day Range
$0.75
$1.07
52-Week Range
$0.74
$9.37
Volume
309,224 shs
Average Volume
666,584 shs
Market Capitalization
$40.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50
30 days | 90 days | 365 days | Advanced Chart

Receive AVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter.

AVRO Stock Forecast (MarketRank)

Overall MarketRank

2.16 out of 5 stars

Medical Sector

432nd out of 1,433 stocks

Biological Products, Except Diagnostic Industry

72nd out of 217 stocks

Analyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
AVROBIO logo

About AVROBIO (NASDAQ:AVRO)

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

AVRO Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVRO
Fax
N/A
Employees
122
Year Founded
N/A

Company Calendar

Last Earnings
5/10/2022
Today
6/30/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$7.50
High Stock Price Forecast
$23.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+715.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.66666666666667
Research Coverage
6 Analysts

Profitability

Net Income
$-119.13 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.88 per share

Miscellaneous

Free Float
40,899,000
Market Cap
$40.20 million
Optionable
Not Optionable
Beta
1.72














AVROBIO Frequently Asked Questions

Should I buy or sell AVROBIO stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AVROBIO stock.
View analyst ratings for AVROBIO
or view top-rated stocks.

What is AVROBIO's stock price forecast for 2022?

6 equities research analysts have issued twelve-month target prices for AVROBIO's stock. Their AVRO stock forecasts range from $3.00 to $23.00. On average, they predict AVROBIO's share price to reach $7.50 in the next year. This suggests a possible upside of 715.2% from the stock's current price.
View analysts' price targets for AVROBIO
or view top-rated stocks among Wall Street analysts.

How has AVROBIO's stock price performed in 2022?

AVROBIO's stock was trading at $3.85 at the beginning of 2022. Since then, AVRO shares have decreased by 76.1% and is now trading at $0.92.
View the best growth stocks for 2022 here
.

When is AVROBIO's next earnings date?

AVROBIO is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for AVROBIO
.

How were AVROBIO's earnings last quarter?

AVROBIO, Inc. (NASDAQ:AVRO) posted its earnings results on Tuesday, May, 10th. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by $0.10.
View AVROBIO's earnings history
.

Who are AVROBIO's key executives?

AVROBIO's management team includes the following people:
  • Mr. Geoff MacKay BSc, Co- Founder, Pres, CEO & Director (Age 56, Pay $754.39k)
  • Mr. Erik John Ostrowski M.B.A., CFO & Treasurer (Age 49, Pay $554.66k)
  • Dr. Christopher Mason FMEDSCI, FRCS, M.D., Ph.D., Chief Scientific Officer (Age 63, Pay $521.28k)
  • Mr. Jeffrey Medin Ph.D., Scientific Founder
  • Mr. Matthew Arnold, Head of Operations
  • Mr. Steven N. Avruch J.D., Chief Legal Officer & Sec. (Age 61)
  • Ms. Monique Da Silva, Sr. VP of Corp. Communications
  • Ms. Deanna M. Petersen MBA, Chief Bus. Officer (Age 60)
  • Ms. Holly May, Chief Commercial Officer
  • Mr. Kim Raineri M.B.A., Chief Manufacturing & Technical Operations Officer

What other stocks do shareholders of AVROBIO own?

When did AVROBIO IPO?

(AVRO) raised $75 million in an IPO on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager.

What is AVROBIO's stock symbol?

AVROBIO trades on the NASDAQ under the ticker symbol "AVRO."

How do I buy shares of AVROBIO?

Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AVROBIO's stock price today?

One share of AVRO stock can currently be purchased for approximately $0.92.

How much money does AVROBIO make?

AVROBIO (NASDAQ:AVRO) has a market capitalization of $40.20 million. The company earns $-119.13 million in net income (profit) each year or ($2.82) on an earnings per share basis.

How many employees does AVROBIO have?

AVROBIO employs 122 workers across the globe.

How can I contact AVROBIO?

AVROBIO's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The official website for AVROBIO is www.avrobio.com. The company can be reached via phone at (617) 914-8420 or via email at [email protected].

This page (NASDAQ:AVRO) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.